{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-006992","form_type":"8-K","ticker":"AMRN","cik":"0000897448","company_name":"AMARIN CORP PLCUK","filed_at":"2026-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.988051+00:00","generated_at":"2026-05-16T11:17:49.027425+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Amarin achieves positive cash flow in Q4 2025 ahead of schedule; FY revenue $212-217M","bullets":["Year-end cash $303M, up $16M from Q3; no debt; Q4 positive cash flow achieved earlier than forecast.","Q4 2025 net revenue expected $48-53M; FY 2025 net revenue $212-217M.","Restructuring: 50% of $70M OPEX savings realized; full benefit on track by June 30, 2026. Estimated restructuring costs raised to $37-40M.","VASCEPA >50% IPE prescription share in US; Recordati now managing European commercialization in most launched countries.","Two new regulatory approvals (South Korea and Singapore); >10 abstracts and >20 manuscripts published in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-006992","json":"https://secwatch.observer/filing/0001193125-26-006992.json","markdown":"https://secwatch.observer/filing/0001193125-26-006992.md","text":"https://secwatch.observer/filing/0001193125-26-006992.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/897448/000119312526006992/0001193125-26-006992-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/897448/000119312526006992/amrn-20260108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:17:49.027425+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}